argenx NV ADR (ARGX) - Net Assets
Based on the latest financial reports, argenx NV ADR (ARGX) has net assets worth $7.32 Billion USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($8.68 Billion) and total liabilities ($1.36 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore cash flow conversion of argenx NV ADR to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $7.32 Billion |
| % of Total Assets | 84.34% |
| Annual Growth Rate | 54.99% |
| 5-Year Change | 188.97% |
| 10-Year Change | 10887.22% |
| Growth Volatility | 126.7 |
argenx NV ADR - Net Assets Trend (2010–2025)
This chart illustrates how argenx NV ADR's net assets have evolved over time, based on quarterly financial data. For live valuation and market cap data, see ARGX stock market capitalisation.
Annual Net Assets for argenx NV ADR (2010–2025)
The table below shows the annual net assets of argenx NV ADR from 2010 to 2025. Read ARGX total debt and obligations for a breakdown of total debt and financial obligations.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $7.32 Billion | +33.19% |
| 2024-12-31 | $5.50 Billion | +34.19% |
| 2023-12-31 | $4.10 Billion | +45.63% |
| 2022-12-31 | $2.81 Billion | +11.03% |
| 2021-12-31 | $2.53 Billion | +51.38% |
| 2020-12-31 | $1.67 Billion | +41.82% |
| 2019-12-31 | $1.18 Billion | +91.66% |
| 2018-12-31 | $615.87 Million | +48.83% |
| 2017-12-31 | $413.81 Million | +520.87% |
| 2016-12-31 | $66.65 Million | +63.29% |
| 2015-12-31 | $40.82 Million | -15.43% |
| 2014-12-31 | $48.26 Million | +61.02% |
| 2013-12-31 | $29.97 Million | +79.99% |
| 2012-12-31 | $16.65 Million | -40.31% |
| 2011-12-31 | $27.90 Million | +172.65% |
| 2010-12-31 | $10.23 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to argenx NV ADR's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 27135900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $7.35 Million | 0.10% |
| Other Comprehensive Income | $73.59 Million | 1.00% |
| Other Components | $7.52 Billion | 102.72% |
| Total Equity | $7.32 Billion | 100.00% |
argenx NV ADR Competitors by Market Cap
The table below lists competitors of argenx NV ADR ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ING Groep N.V
MX:INGN
|
$46.00 Billion |
|
Shanghai Pudong Development Bank Co Ltd
SHG:600000
|
$46.06 Billion |
|
Hess Corporation
NYSE:HES
|
$46.07 Billion |
|
Franco-Nevada Corporation
TO:FNV
|
$46.18 Billion |
|
Ambev SA ADR
NYSE:ABEV
|
$45.92 Billion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
$45.88 Billion |
|
HOLCIM NEW(U.ADR)1/5/SF2
F:HLB
|
$45.78 Billion |
|
KBC GROEP N.V. ADR
F:KDB0
|
$45.62 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in argenx NV ADR's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,498,283,000 to 7,323,092,000, a change of 1,824,809,000 (33.2%).
- Net income of 1,296,032,818 contributed positively to equity growth.
- Other comprehensive income increased equity by 6,879,999.
- Other factors increased equity by 521,896,183.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $1.30 Billion | +17.7% |
| Other Comprehensive Income | $6.88 Million | +0.09% |
| Other Changes | $521.90 Million | +7.13% |
| Total Change | $- | 33.19% |
Book Value vs Market Value Analysis
This analysis compares argenx NV ADR's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.10x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 443.57x to 7.10x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $1.78 | $787.95 | x |
| 2012-12-31 | $1.06 | $787.95 | x |
| 2013-12-31 | $1.91 | $787.95 | x |
| 2014-12-31 | $3.88 | $787.95 | x |
| 2015-12-31 | $2.59 | $787.95 | x |
| 2016-12-31 | $3.54 | $787.95 | x |
| 2017-12-31 | $16.81 | $787.95 | x |
| 2018-12-31 | $17.12 | $787.95 | x |
| 2019-12-31 | $30.57 | $787.95 | x |
| 2020-12-31 | $36.87 | $787.95 | x |
| 2021-12-31 | $49.62 | $787.95 | x |
| 2022-12-31 | $51.74 | $787.95 | x |
| 2023-12-31 | $71.67 | $787.95 | x |
| 2024-12-31 | $84.36 | $787.95 | x |
| 2025-12-31 | $110.91 | $787.95 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently argenx NV ADR utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 17.70%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 31.12%
- • Asset Turnover: 0.48x
- • Equity Multiplier: 1.19x
- Recent ROE (17.70%) is above the historical average (-20.31%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | -16.10% | -308.02% | 0.05x | 1.14x | $-7.28 Million |
| 2012 | -77.02% | -587.54% | 0.10x | 1.38x | $-14.49 Million |
| 2013 | -28.25% | -229.00% | 0.11x | 1.15x | $-11.46 Million |
| 2014 | -20.59% | -274.62% | 0.08x | 0.96x | $-18.63 Million |
| 2015 | -41.08% | -223.42% | 0.15x | 1.23x | $-20.82 Million |
| 2016 | -33.73% | -145.27% | 0.14x | 1.67x | $-29.14 Million |
| 2017 | -8.14% | -77.10% | 0.10x | 1.08x | $-75.06 Million |
| 2018 | -12.38% | -310.22% | 0.04x | 1.07x | $-137.82 Million |
| 2019 | -15.35% | -230.95% | 0.05x | 1.36x | $-299.25 Million |
| 2020 | -36.35% | -1475.29% | 0.02x | 1.36x | $-775.86 Million |
| 2021 | -16.08% | -81.97% | 0.17x | 1.12x | $-661.05 Million |
| 2022 | -25.22% | -172.76% | 0.13x | 1.11x | $-990.96 Million |
| 2023 | -7.20% | -24.06% | 0.27x | 1.11x | $-704.80 Million |
| 2024 | 15.15% | 38.03% | 0.35x | 1.13x | $283.21 Million |
| 2025 | 17.70% | 31.12% | 0.48x | 1.19x | $563.72 Million |
Industry Comparison
This section compares argenx NV ADR's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $144,537,792
- Average return on equity (ROE) among peers: -354.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| argenx NV ADR (ARGX) | $7.32 Billion | -16.10% | 0.19x | $45.97 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $117.36 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $681.00K | -3192.95% | 12.43x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $185.59 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $45.35 Million | -59.09% | 0.17x | $821.01 Million |
| ABVC Biopharma Inc (ABVC) | $-2.01 Million | 0.00% | 0.00x | $27.43 Million |
| Abivax SA American Depositary Shares (ABVX) | $17.90 Million | -209.78% | 2.98x | $9.08 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.74 Billion |
About argenx NV ADR
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgarti… Read more